Comparing the efficacy of topical hydroquinone 2% versus intradermal tranexamic acid microinjections in treating melasma: a split-face controlled trial

References

• Prignano F, Ortonne JP, Buggiani G, et al. Therapeutical approaches in melasma. Dermatol Clin. 2007;25:337–342.
   PubMed Web of Science ®Google Scholar
• Victor FC, Gelber J, Rao B. Melasma: a review. J Cutan Med Surg. 2004;8:97–102.
   PubMed Web of Science ®Google Scholar
• Burns T, Breathnach S, Cox N, et al. Rook’s textbook of dermatology. Oxford: Willy–Blackwell; 2010:58.34.
   Google Scholar
• Bolognia JL, Jorrizo JL, Schaffer JV, et al. Dermatology. London, UK: Elsevier; 2012. p. 1052–1053.
   Google Scholar
• Miot LD, Miot HA, Silva MG, et al. Physiopathology of melasma. An Bras Dermatol. 2006;84:623–635.
   Google Scholar
• Ho SG, Chan HH. The Asian dermatologic patient: review of common pigmentary disorders and cutaneous diseases. Am J Clin Dermatol. 2009;10:153–168.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Gover MD, Nouri K, et al. The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55:1048–1065.
   PubMed Web of Science ®Google Scholar
• Grimes PE. Melasma. Etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453–1457.
   PubMed Web of Science ®Google Scholar
• Tse TW, Hui E. Tranexamic acid: an important adjuvant in the treatment of melasma. J Cosmet Dermatol. 2013;12:57–66.
   PubMed Web of Science ®Google Scholar
• Sehgal VN, Verma P, Srivastava G, et al. Melasma: treatment strategy. J Cosmet Laser Ther. 2011;13:265–279.
   PubMed Web of Science ®Google Scholar
• Rendon M, Berneburg M, Arellano I, et al. Treatment of melasma. J Am Acad Dermatol. 2006;54:S272–S281.
   PubMed Web of Science ®Google Scholar
• Costin GE, Birlea SA. What is the mechanism for melasma that so commonly accompanies human pregnancy? IUBMB Life. 2006;58:55–57.
   PubMed Web of Science ®Google Scholar
• Kang HY, Valerio L, Bahadoran P, et al. The role of topical retinoids in the treatment of pigmentary disorders: an evidence-based review. Am J Clin Dermatol. 2009;10:251–260.
   PubMed Web of Science ®Google Scholar
• Kang HY, Ortonne JP. What should be considered in treatment of melasma. Ann Dermatol. 2010;22:373–378.
   PubMed Web of Science ®Google Scholar
• Shankar K, Godse K, Aurangabadkar S, et al. Evidence-based treatment for melasma: expert opinion and a review. Dermatol Ther (Heidelb). 2014;4:165–186.
   PubMedGoogle Scholar
• Taraz M, Niknam S, Ehsani AH. Tranexamic acid in treatment of melasma: a comprehensive review of clinical studies. Dermatol Ther. 2017;30(3):e12465. doi: 10.1111/dth.12465
   Web of Science ®Google Scholar
• Higashi N. Treatment of melasma with oral tranexamic acid. Skin Res. 1988;30:676–680.
   Google Scholar
• R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016. URL: http://www.R-project.org/
   Google Scholar
• Jimbow K, Obata H, Pathak MA, et al. Mechanism of depigmentation by hydroquinone. J Invest Dermatol. 1974;62:436–449.
   PubMed Web of Science ®Google Scholar
• Briganti S, Camera E, Picardo M. Chemical and instrumental approaches to treat hyperpigmentation. Pigment Cell Res. 2003;16:101–110.
   PubMedGoogle Scholar
• Bentley-Phillips B, Bayles MA. Cutaneous reactions to topical application of hydroquinone. Results of a 6-year investigation. S Afr Med J. 1975;49:1391–1395.
   PubMed Web of Science ®Google Scholar
• Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl (Stockh). 1989;143:58–61.
   PubMedGoogle Scholar
• Shin JU, Park J, Oh SH, Lee JH. Oral tranexamic acid enhances the efficacy of low-fluence 1064-nm qualityswitched neodymium-doped yttrium aluminum garnet laser treatment for Melasma in Koreans: a randomized, prospective trial. Dermatol Surg. 2013;39:435–442.
   PubMed Web of Science ®Google Scholar
• Tomita Y, Iwamoto M, Masuda T, et al. Stimulatory effect of prostaglandin E2 on the configuration of normal human melanocytes in vitro. J Invest Dermatol. 1987;89:299–301.
   PubMed Web of Science ®Google Scholar
• Tomita Y, Maeda K, Tagami H. Leukotrienes and thromboxane B2 stimulate normal human melanocytes in vitro: possible inducers of postinflammatory pigmentation. Tohoku J Exp Med. 1988;156:303–304.
   PubMed Web of Science ®Google Scholar
• Falcone JJ, McCaffrey TA, Haimovitz Friedman A, et al. Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation. J Biol Chem. 1993;268:11951–11958.
   PubMed Web of Science ®Google Scholar
• Karn D, Kc S, Amatya A, et al. Oral tranexamic acid for the treatment of melasma. Kathmandu Univ Med J (KUMJ). 2012;10:40–43.
   PubMedGoogle Scholar
• Na JI, Choi SY, Yang SH, et al. Effect of tranexamic acid on melasma: a clinical trial with histological evaluation. J Eur Acad Dermatol Venereol. 2013;27:1035–1039.
   PubMed Web of Science ®Google Scholar
• Tan AW, Sen P, Chua SH, et al. Oral tranexamic acid lightens refractory melasma. Australas J Dermatol. 2016;58(3).
   PubMed Web of Science ®Google Scholar
• Perper M, Eber AE, Fayne R, et al. Tranexamic acid in the treatment of melasma: a review of the literature. Am J Clin Dermatol. 2017;10:1–9.
   Google Scholar
• Kim HJ, Moon SH, Cho SH, et al. Efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review. Acta Derm Venereol. 2017;97:776–781.
   PubMed Web of Science ®Google Scholar
• Lee JH, Park JG, Lim SH, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol Surg. 2006;32:626–631.
   PubMed Web of Science ®Google Scholar
• Steiner D, Feola C, Bialeski N, et al. Study evaluating the efficacy of topical and injected tranexamic acid in treatment of melasma. Surg Cosmet Dermatol. 2009;1:174–177.
   Google Scholar
• Budamakuntla L, Loganathan E, Suresh DH, et al. A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma. J Cutan Aesthet Surg. 2013;6:139.
   PubMedGoogle Scholar
• Mangal S, Parsad D. Tranexamic acid microinjections in melasma-a pilot study. Pigment Cell Melanoma Res. 2014;27:966.
   Google Scholar
• Elfar NN, El-Maghraby GM. Efficacy of intradermal injection of ranexamic acid, topical silymarin and glycolic acid peeling in treatment of melasma: a comparative study. J Clin Exp Dermatol Res. 2015;6(280):2.
   Google Scholar
• Cestari TF, Hassun K, Sittart A, et al. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. J Cosmet Dermat. 2007;6:36–39.
   PubMedGoogle Scholar
• Fabi SG, Friedmann DP, Massaki N, et al. A randomized, split‐face clinical trial of low‐fluence Q‐switched neodymium‐doped yttrium aluminum garnet (1064 nm) laser versus low‐fluence Q‐switched alexandrite laser (755 nm) for the treatment of facial melasma. Lasers Surg Med. 2014;46:531–537.
   PubMed Web of Science ®Google Scholar
• Baquié M, Kasraee B. Discrimination between cutaneous pigmentation and erythema: comparison of the skin colorimeters Dermacatch and Mexameter. Skin Res Technol. 2014;20:218–227.
   PubMed Web of Science ®Google Scholar
• Cho HH, Choi M, Cho S, et al. Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd:YAG laser. J Dermatolog Treat. 2013;24:292–296.
   PubMed Web of Science ®Google Scholar